Together with Sapphiros, The US Biomedical Advanced Research and Development Authority (BARDA) is developing an over the counter (OTC), single-use, low-cost antigen test that can detect and differentiate between respiratory viruses.

Agreement secures rapid, global access to tests for future pandemics and health emergencies. Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros’ 5 billion unit capacity proprietary manufacturing process.

Satio announced today that it completed a Small Business Innovation Research (SBIR) contract for its intradermal drug delivery system.

Mr. McAdam will be responsible for overseeing the global finance and information technology functions.

Sapphiros, a leading consumer diagnostics company, has launched its new direct-to-consumer wellness brand, NowFuture™.

Sapphiros announced continuation of support from the Rapid Acceleration of Diagnostics (RADx®) program to support the development of a molecular respiratory at-home diagnostic

Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc., formerly AmerisourceBergen Corporation.

Satio is pleased to announce a $3.5 million Small Business Innovation Research (SBIR) contract awarded by the Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services.

Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.

Sapphiros, a platform dedicated to building the next generation of consumer diagnostics, is pleased to announce the appointment of Andrew Garfield as its new Vice President of Operations.

GrapheneDxTM, General Graphene Corporation and SapphirosTM announce a strategic partnership to industrialize graphene-based biosensors for medical devices used to diagnose a variety of diseases at the point-of-care and in consumer settings.

Sapphiros has been selected by the National Institutes of Health (NIH) to develop a high performance, over-the-counter, molecular multiplex respiratory diagnostic test that can rapidly detect RSV, influenza A, influenza B and COVID-19.

Sapphiros, a platform dedicated to building the next generation of consumer diagnostics, backed by KKR, is pleased to announce the appointment of Teresa Abraham, PhD, as its new Vice President of Scientific and Technical Affairs

Biocrucible, a Sapphiros platform company dedicated to building the next generation of consumer diagnostics, announced the appointment of Per Grufman, Ph.D., as its Chief Executive Officer.

Sapphiros, a platform dedicated to building the next generation of consumer diagnostic technologies, today announced the promotion of Mark Gladwell, Sapphiros's Chief Operating Officer ("COO") to President and Chief Executive Officer ("CEO").

Sapphiros has today completed the acquisition of Flexotronix Limited. Flexotronix have developed a high speed printed electronics manufacturing line using in-house proprietary conductive inks and printed components.

Sapphiros announced today that Mike Musgnug has joined the company as EVP Strategy for Sapphiros and CEO of GrapheneDX, a Sapphiros Group Company

The partnership aims to enable low-cost access to vaccines and diagnostics to advance public health in Africa and beyond.

Satio and INTACT Solutions have entered into an agreement to establish a collaborative framework in order to partner on research, development, manufacture, and deployment of next generation health technologies.

KR-backed platform building the next generation of diagnostic technologies, today announced the appointment of Mark Gladwell as Chief Operating Officer and Dr. Niall Armes as Chief Technology Officer

Biocrucible Ltd has received funding from the Bill & Melinda Gates Foundation to explore rapid molecular testing options for COVID-19 and other pathogens, which could be used in the home or in field settings.